Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 IBI306 (Tafolecimab) in Hypercholesterolemia
NCT03815812Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Mar 2019
- Primary completion
- Dec 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypercholesterolemia comparing IBI306 with Placebo (2 arms). Primary endpoint: Adverse Events and Serious Adverse Events up to 12 weeks. Started Mar 2019; status: completed.
02
Drugs
tafolecimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03815812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815812.